Veracyte ROE 2024

Veracyte ROE

-0.07

Veracyte Dividend yield

Ticker

VCYT

ISIN

US92337F1075

WKN

A1W7EA

In 2024, Veracyte's return on equity (ROE) was -0.07, a 109.34% increase from the -0.03 ROE in the previous year.

Veracyte Aktienanalyse

What does Veracyte do?

Veracyte Inc is a company that specializes in the development and marketing of diagnostic tests for a wide range of diseases and disorders. The company was founded in 2008 and is headquartered in South San Francisco, California. The history of Veracyte Inc begins with the vision to help patients with better diagnostic options. The company has used its expertise in gene expression technology to develop tests that facilitate the diagnosis of diseases and disorders in various areas, such as cancer, thyroid diseases, and lung diseases. Veracyte Inc's business model is based on selling diagnostic tests to healthcare facilities, hospitals, doctors, and other medical institutions. The tests are performed by specially trained professionals and can provide a precise diagnosis that helps doctors plan individualized treatment. Veracyte Inc is divided into different divisions to offer the best and most precise test for each area. The divisions include cancer diagnosis, thyroid diagnostics, lung diagnostics, and other areas of gene expression technology. In cancer diagnosis, Veracyte Inc offers tests for various types of cancer, such as breast cancer, thyroid cancer, and lung cancer. The tests use RNA sequencing to analyze the patient's genetic information and provide a more precise diagnosis. In thyroid diagnostics, Veracyte Inc offers tests for various thyroid diseases that are often difficult to diagnose. The tests help avoid unnecessary surgeries or medical interventions and enable patients to receive a more accurate diagnosis and treatment. In lung diagnostics, Veracyte Inc offers tests for pneumonia, lung cancer, and other lung diseases. The tests use RNA sequencing and imaging to provide accurate diagnoses that help doctors recommend tailored treatment. In addition to these divisions, Veracyte Inc also offers other products and services, such as information campaigns and training for healthcare professionals, as well as support and counseling for patients and their families. Overall, Veracyte Inc aims to revolutionize the medical field and provide patients with better diagnosis and treatment options. The company's tests offer doctors and patients a more precise and personalized diagnosis, allowing for individualized treatment and achieving the best results. Veracyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Veracyte's Return on Equity (ROE)

Veracyte's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Veracyte's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Veracyte's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Veracyte’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Veracyte Stock

What is the ROE (Return on Equity) of Veracyte this year?

The ROE of Veracyte this year is -0.07 undefined.

How has the Return on Equity (ROE) of Veracyte developed compared to the previous year?

The ROE of Veracyte has increased by 109.34% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Veracyte?

A high ROE indicates that Veracyte generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Veracyte?

A low ROE can indicate that Veracyte is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Veracyte affect the company?

A change in ROE (Return on Equity) of Veracyte can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Veracyte?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Veracyte?

Some factors that can influence Veracyte's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Veracyte pay?

Over the past 12 months, Veracyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Veracyte is expected to pay a dividend of 0 USD.

What is the dividend yield of Veracyte?

The current dividend yield of Veracyte is .

When does Veracyte pay dividends?

Veracyte pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Veracyte?

Veracyte paid dividends every year for the past 0 years.

What is the dividend of Veracyte?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Veracyte located?

Veracyte is assigned to the 'Health' sector.

Wann musste ich die Aktien von Veracyte kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Veracyte from 5/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/27/2024.

When did Veracyte pay the last dividend?

The last dividend was paid out on 5/27/2024.

What was the dividend of Veracyte in the year 2023?

In the year 2023, Veracyte distributed 0 USD as dividends.

In which currency does Veracyte pay out the dividend?

The dividends of Veracyte are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Veracyte stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Veracyte

Our stock analysis for Veracyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Veracyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.